Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 4 Interventional Results available

A 12-Month Study Comparing Fluticasone Propionate/Salmeterol (ADVAIR) DISKUS Combination Product 250/50mcg BID To Fluticasone Propionate (FLOVENT) DISKUS 250 mcg BID In Symptomatic Subjects With Asthma

ClinicalTrials.gov ID: NCT00452699

Public ClinicalTrials.gov record NCT00452699. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 4:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A 52-week, Randomized, Double-Blind, Parallel-Group Study of Fluticasone Propionate/Salmeterol DISKUS Combination Product (FSC) 250/50 mcg BID and Fluticasone Propionate (FP) DISKUS 250 mcg BID in Treatment of Subjects With Asthma

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This purpose of this study is to show the superiority and long term safety and efficacy of adding a long acting beta agonist (salmeterol) to constant dose of an inhaled corticosteroid (fluticasone propionate) in symptomatic subjects with asthma. The 12-month assessment of asthma control will provide key information on the efficacy and safety of the combination therapy. The safety measure will be an assessment of adverse events

Study identification

NCT ID
NCT00452699
Recruitment status
Completed
Study type
Interventional
Phase
Phase 4
Lead sponsor
GlaxoSmithKline
Industry
Enrollment
621 participants

Conditions and interventions

Eligibility (public fields only)

Age range
12 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 2007 (Type not available)
Primary completion
May 2009 (Actual)
Completion
May 2009 (Actual)
Last update posted
Dec 8, 2016

2007 – 2009

United States locations

U.S. sites
58
U.S. states
26
U.S. cities
51
Facility City State ZIP Site status
GSK Investigational Site Scottsdale Arizona 85251 —
GSK Investigational Site Little Rock Arkansas 72205 —
GSK Investigational Site Fountain Valley California 92708 —
GSK Investigational Site Los Angeles California 90095-1690 —
GSK Investigational Site Rancho Mirage California 92270 —
GSK Investigational Site Riverside California 92506 —
GSK Investigational Site San Jose California 95117 —
GSK Investigational Site Denver Colorado 80206 —
GSK Investigational Site Denver Colorado 80230 —
GSK Investigational Site Fort Collins Colorado 80526 —
GSK Investigational Site Fort Collins Colorado 80528 —
GSK Investigational Site Stamford Connecticut 06902 —
GSK Investigational Site Coral Gables Florida 33134 —
GSK Investigational Site Miami Florida 33173 —
GSK Investigational Site Pensacola Florida 32504 —
GSK Investigational Site Tallahassee Florida 32308 —
GSK Investigational Site Tamarac Florida 33321 —
GSK Investigational Site Columbus Georgia 31904 —
GSK Investigational Site Conyers Georgia 30013 —
GSK Investigational Site Lilburn Georgia 30047 —
GSK Investigational Site South Bend Indiana 46617 —
GSK Investigational Site Metairie Louisiana 70006 —
GSK Investigational Site Bethesda Maryland 20814 —
GSK Investigational Site Wheaton Maryland 20902 —
GSK Investigational Site Ypsilanti Michigan 48197 —
GSK Investigational Site St Louis Missouri 63104 —
GSK Investigational Site Billings Montana 59102 —
GSK Investigational Site Bozeman Montana 59718 —
GSK Investigational Site Omaha Nebraska 68130 —
GSK Investigational Site Cherry Hill New Jersey 08003 —
GSK Investigational Site Great Neck New York 11023 —
GSK Investigational Site New York New York 10021 —
GSK Investigational Site Utica New York 13502 —
GSK Investigational Site Asheville North Carolina 28801 —
GSK Investigational Site High Point North Carolina 27262 —
GSK Investigational Site Cincinnati Ohio 45231 —
GSK Investigational Site Portland Oregon 97213 —
GSK Investigational Site Tigard Oregon 97223 —
GSK Investigational Site Philadelphia Pennsylvania 19107 —
GSK Investigational Site Philadelphia Pennsylvania 19140 —
GSK Investigational Site Pittsburgh Pennsylvania 15241 —
GSK Investigational Site Pittsburgh Pennsylvania 15243 —
GSK Investigational Site East Providence Rhode Island 02914 —
GSK Investigational Site Providence Rhode Island 02906 —
GSK Investigational Site Providence Rhode Island 02909 —
GSK Investigational Site Gaffney South Carolina 29340 —
GSK Investigational Site Orangeburg South Carolina 29118 —
GSK Investigational Site Spartanburg South Carolina 29303 —
GSK Investigational Site Union South Carolina 29309 —
GSK Investigational Site Austin Texas 78750 —
GSK Investigational Site Corsicana Texas 75110 —
GSK Investigational Site El Paso Texas 79925 —
GSK Investigational Site Houston Texas 77030 —
GSK Investigational Site Houston Texas 77054 —
GSK Investigational Site Richmond Virginia 23225 —
GSK Investigational Site Richmond Virginia 23229 —
GSK Investigational Site Olympia Washington 98506 —
GSK Investigational Site West Allis Wisconsin 53227 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 16 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00452699, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 8, 2016 · Synced Oct 17, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00452699 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →